UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...

Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...

In this discussion, Matthew Cooperberg, MD, speaks with Monique Roobol, PhD, lead author of the NEJM publication “European Study of Prostate Cancer Screening - 23-Year Follow-up.” Dr. Roobol reviews ...

Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...

Daniel George presents the CAPItello-281 study examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. The study screened over 6,000 patients ...

Scott Sellinger discusses federal government shutdown impacts on healthcare delivery with Phillip Koo, highlighting critical operational challenges facing independent urology practices. Medicare ...

Login to update email address, newsletter preferences and use bookmarks.

At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman discusses his team's work with Terbium-161 in the VIOLET clinical trial at Peter Mac. He explains Terbium-161 offers both beta and Auger electron ...

At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...

Focal therapy (FT) has quickly emerged over the last few decades as a prostate cancer (CaP) treatment option due to the growing research indicating more favorable side effects compared to radical ...

At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...